# Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection

> **NCT02250807** · PHASE3 · COMPLETED · sponsor: **Janssen R&D Ireland** · enrollment: 40 (actual)

## Conditions studied

- Chronic Hepatitis C
- Genotype 4 Chronic Hepatitis C

## Interventions

- **DRUG:** Simeprevir
- **DRUG:** Sofosbuvir

## Key facts

- **NCT ID:** NCT02250807
- **Lead sponsor:** Janssen R&D Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02250807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02250807, "Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02250807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*